We are initiating coverage on Rocket Pharmaceuticals with a Buy rating and a $17 price target (2-3 years). The company has an enterprise value, EV, of $151M at present, a valuation that implied near ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback